HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.

Abstract
Behavioral and psychological symptoms of dementia (BPSD) include apathy, sleep problems, irritability, wandering, elation, agitation/aggression, and mood disorders such as depression and/or anxiety. Elderly patients are usually treated with second-generation antipsychotics; however, they present not enough efficacy against all symptoms observed. Hence, there still is an unmet need for novel pharmacotherapeutic agents targeted BPSD. A novel arylsulfonamide derivative ADN-1184 has been developed that possesses a preclinical profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances. To broaden its pharmacological efficacy toward anxiety symptoms, its anxiolytic properties have been examined in common animal preclinical models in rats and mice. ADN-1184 significantly increased the number of entries into open arms measured in the elevated plus-maze test; however, it simultaneously increased parameters of exploratory activity. In the Vogel conflict drinking test, ADN-1184 dose-dependently and significantly increased the number of shocks accepted and the number of licks. Moreover, in mice, it also had specific anxiolytic-like activity in the four-plate test, and only negligible one at a specific mid-range dose measured in the spontaneous marble burying test. The obtained findings reveal that ADN-1184 displays anxiolytic-like activity in animal models of anxiety which employed punished stimuli. In its unusual combination of some anxiolytic action with already proven antipsychotic and antidepressant properties, and lack of any disruptive impact on learning and memory processes and motor coordination, ADN-1184 displays a profile that would be desired for a novel therapeutic for BPSD.
AuthorsAnna Partyka, Anna Wasik, Magdalena Jastrzębska-Więsek, Paweł Mierzejewski, Przemysław Bieńkowski, Marcin Kołaczkowski, Anna Wesołowska
JournalNaunyn-Schmiedeberg's archives of pharmacology (Naunyn Schmiedebergs Arch Pharmacol) Vol. 389 Issue 6 Pg. 593-602 (Jun 2016) ISSN: 1432-1912 [Electronic] Germany
PMID26979176 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • ADN-1184
  • Anti-Anxiety Agents
  • Isoxazoles
  • Receptors, Serotonin
  • Serotonin Antagonists
  • Sulfonamides
  • serotonin 6 receptor
  • serotonin 7 receptor
  • Benzodiazepines
  • Aripiprazole
  • Risperidone
  • Olanzapine
Topics
  • Animals
  • Anti-Anxiety Agents (pharmacology)
  • Anxiety (drug therapy, metabolism, psychology)
  • Aripiprazole (pharmacology)
  • Behavior, Animal (drug effects)
  • Benzodiazepines (pharmacology)
  • Conditioning, Psychological (drug effects)
  • Conflict, Psychological
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Exploratory Behavior (drug effects)
  • Isoxazoles (pharmacology)
  • Male
  • Maze Learning (drug effects)
  • Mice
  • Motor Activity (drug effects)
  • Olanzapine
  • Punishment
  • Rats, Wistar
  • Reaction Time (drug effects)
  • Receptors, Serotonin (drug effects, metabolism)
  • Risperidone (pharmacology)
  • Serotonin Antagonists (pharmacology)
  • Sulfonamides (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: